BioXcel Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference
July 19 2021 - 7:30AM
BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq:
BTAI), today announced that Dr. Vimal Mehta, Ph.D., Founder and
Chief Executive Officer of BioXcel, will participate in the
Canaccord Genuity 41st Annual Growth Conference on Thursday, August
12, 2021 at 9:30 a.m. Eastern Time.
To access the live webcast of BioXcel’s
presentation, please visit the “Events” page within the News &
Media section of the Company's website at
www.bioxceltherapeutics.com. A replay of the webcast will be
available on the Company’s website for at least 30 days following
the event.
About BioXcel Therapeutics,
Inc.
BioXcel Therapeutics, Inc. is a clinical-stage
biopharmaceutical company utilizing artificial intelligence
approaches to develop transformative medicines in neuroscience and
immuno-oncology. BioXcel’s drug re-innovation approach leverages
existing approved drugs and/or clinically validated product
candidates together with big data and proprietary machine learning
algorithms to identify new therapeutic indices. BioXcel’s two most
advanced clinical development programs are BXCL501, an
investigational, proprietary, orally dissolving thin film
formulation of dexmedetomidine for the treatment of agitation and
opioid withdrawal symptoms, and BXCL701, an investigational, orally
administered, systemic innate immunity activator in development for
the treatment of aggressive forms of prostate cancer and advanced
solid tumors that are refractory or treatment naïve to checkpoint
inhibitors. For more information, please visit
www.bioxceltherapeutics.com.
Source: BioXcel Therapeutics, Inc.
Investor & Media:
Mary Coleman
mcoleman@bioxceltherapeutics.com
475-238-6837
BioXcel Therapeutics (NASDAQ:BTAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioXcel Therapeutics (NASDAQ:BTAI)
Historical Stock Chart
From Apr 2023 to Apr 2024